Sean A. McCarthy
Insider (Form 4 reporting owner): CEO CIK 1654058Name as filed: McCarthy Sean A.Its filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 3 Mar 2017, sold $8.6M in 36 sales (2 under a 10b5-1 plan set in advance) of CytomX Therapeutics.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| CytomX Therapeutics CTMX | CEO | 3 Mar 2017 | 17 Mar 2026 | – | 36$8.6M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | -40.0 pts29 trades, 14% above the sector | -77.3 pts29 trades, 14% above the sector | -76.5 pts28 trades, 18% above the sector |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 1 | $764K | -$764K |
| 2025 | – | – | 3 | $634K | -$634K |
| 2024 | – | – | 2 | $59K | -$59K |
| 2023 | – | – | 3 | $51K | -$51K |
| 2022 | – | – | 1 | $21K | -$21K |
| 2021 | – | – | 2 | $1.5M | -$1.5M |
| 2020 | – | – | 1 | $540K | -$540K |
| 2018 | – | – | 9 | $2.4M | -$2.4M |
| 2017 | – | – | 14 | $2.7M | -$2.7M |
Every trade
39, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 17 Mar 2026 | CytomX Therapeutics CTMX | Sell | 118,969 | $6.42 | $764K | 10b5-1 plan | Form 4filed 19 Mar 2026 |
| 6 Nov 2025 | CytomX Therapeutics CTMX | Sellamended filing (4/A), not counted again; after exercising options | 101,793 | $4.54 | $462K | 10b5-1 plan | Form 4/Afiled 16 Oct 2026 |
| 6 Nov 2025 | CytomX Therapeutics CTMX | Sell | 101,793 | $4.54 | $462K | 10b5-1 plan | Form 4filed 10 Nov 2025 |
| 16 Jun 2025 | CytomX Therapeutics CTMX | Sellafter exercising options | 55,511 | $2.69 | $149K | No | Form 4filed 17 Jun 2025 |
| 18 Mar 2025 | CytomX Therapeutics CTMX | Sell | 37,656 | $0.60 | $23K | No | Form 4filed 20 Mar 2025 |
| 20 Aug 2024 | CytomX Therapeutics CTMX | Sellafter exercising options | 13,898 | $1.23 | $17K | No | Form 4filed 22 Aug 2024 |
| 19 Mar 2024 | CytomX Therapeutics CTMX | Sell | 20,223 | $2.09 | $42K | No | Form 4filed 21 Mar 2024 |
| 20 Dec 2023 | CytomX Therapeutics CTMX | Sell | 13,551 | $1.38 | $19K | No | Form 4filed 22 Dec 2023 |
| 22 Sep 2023 | CytomX Therapeutics CTMX | Sell | 14,601 | $1.30 | $19K | No | Form 4filed 22 Sep 2023 |
| 16 Mar 2023 | CytomX Therapeutics CTMX | Sell | 7,121 | $1.88 | $13K | No | Form 4filed 20 Mar 2023 |
| 20 Jul 2022 | CytomX Therapeutics CTMX | Sell | 14,911 | $1.42 | $21K | Not stated | Form 4filed 21 Jul 2022 |
| 16 Jun 2021 | CytomX Therapeutics CTMX | Sell | 100,000 | $7.04 | $704K | Not stated | Form 4filed 21 Jun 2021 |
| 31 Mar 2021 | CytomX Therapeutics CTMX | Sellafter exercising options | 100,000 | $7.49 | $749K | Not stated | Form 4filed 2 Apr 2021 |
| 12 May 2020 | CytomX Therapeutics CTMX | Sellafter exercising options | 36,000 | $15.00 | $540K | Not stated | Form 4filed 14 May 2020 |
| 1 Nov 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 6,526 | $15.00 | $98K | Not stated | Form 4filed 5 Nov 2018 |
| 4 Sep 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 13,052 | $21.86 | $285K | Not stated | Form 4filed 6 Sep 2018 |
| 5 Jul 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 4,497 | $25.06 | $113K | Not stated | Form 4filed 9 Jul 2018 |
| 3 Jul 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 2,028 | $25.09 | $51K | Not stated | Form 4filed 6 Jul 2018 |
| 2 Jul 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 13,052 | $23.42 | $306K | Not stated | Form 4filed 3 Jul 2018 |
| 1 May 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 19,578 | $26.55 | $520K | Not stated | Form 4filed 2 May 2018 |
| 1 Mar 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 19,578 | $29.43 | $576K | Not stated | Form 4filed 5 Mar 2018 |
| 5 Jan 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 6,526 | $25.01 | $163K | Not stated | Form 4filed 9 Jan 2018 |
| 2 Jan 2018 | CytomX Therapeutics CTMX | Sellafter exercising options | 13,052 | $21.04 | $275K | Not stated | Form 4filed 4 Jan 2018 |
| 1 Dec 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 14,340 | $20.60 | $295K | Not stated | Form 4filed 5 Dec 2017 |
| 1 Nov 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 14,342 | $19.86 | $285K | Not stated | Form 4filed 3 Nov 2017 |
| 4 Oct 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 19,120 | $24.13 | $461K | Not stated | Form 4filed 6 Oct 2017 |
| 2 Oct 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 9,562 | $18.57 | $178K | Not stated | Form 4filed 4 Oct 2017 |
| 1 Sep 2017 | CytomX Therapeutics CTMX | Sellamended filing (4/A), not counted again; after exercising options | 9,930 | $17.33 | $172K | Not stated | Form 4/Afiled 22 Sep 2017 |
| 1 Sep 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 9,930 | $17.32 | $172K | Not stated | Form 4filed 5 Sep 2017 |
| 31 Aug 2017 | CytomX Therapeutics CTMX | Sellamended filing (4/A), not counted again; after exercising options | 18,756 | $17.50 | $328K | Not stated | Form 4/Afiled 22 Sep 2017 |
| 31 Aug 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 18,756 | $17.50 | $328K | Not stated | Form 4filed 1 Sep 2017 |
| 9 Aug 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 4,781 | $15.00 | $72K | Not stated | Form 4filed 11 Aug 2017 |
| 3 Jul 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 4,781 | $15.52 | $74K | Not stated | Form 4filed 6 Jul 2017 |
| 26 Jun 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 4,481 | $15.00 | $67K | Not stated | Form 4filed 27 Jun 2017 |
| 5 Jun 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 300 | $15.00 | $4K | Not stated | Form 4filed 6 Jun 2017 |
| 1 May 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 4,781 | $15.70 | $75K | Not stated | Form 4filed 2 May 2017 |
| 3 Apr 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 9,562 | $17.22 | $165K | Not stated | Form 4filed 5 Apr 2017 |
| 20 Mar 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 14,343 | $19.60 | $281K | Not stated | Form 4filed 21 Mar 2017 |
| 3 Mar 2017 | CytomX Therapeutics CTMX | Sellafter exercising options | 14,343 | $15.00 | $215K | Not stated | Form 4filed 3 Mar 2017 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.